Biliary Cancer
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)
- Details
ClinicalTrials.gov ID:
NCT05948475
Diagnosis Type:
NA
USOR Number:
- Address
,
P: